183 related articles for article (PubMed ID: 38389706)
1. p66Shc deficiency in CLL cells enhances PD-L1 expression and suppresses immune synapse formation.
Lopresti L; Capitani N; Tatangelo V; Tangredi C; Boncompagni G; Frezzato F; Visentin A; Marotta G; Ciofini S; Gozzetti A; Bocchia M; Trentin L; Baldari CT; Patrussi L
Front Cell Dev Biol; 2024; 12():1297116. PubMed ID: 38389706
[No Abstract] [Full Text] [Related]
2. p66Shc Deficiency in Chronic Lymphocytic Leukemia Promotes Chemokine Receptor Expression Through the ROS-Dependent Inhibition of NF-κB.
Tatangelo V; Boncompagni G; Capitani N; Lopresti L; Manganaro N; Frezzato F; Visentin A; Trentin L; Baldari CT; Patrussi L
Front Oncol; 2022; 12():877495. PubMed ID: 35847884
[TBL] [Abstract][Full Text] [Related]
3. Leukemic cell-secreted interleukin-9 suppresses cytotoxic T cell-mediated killing in chronic lymphocytic leukemia.
Boncompagni G; Tatangelo V; Lopresti L; Ulivieri C; Capitani N; Tangredi C; Finetti F; Marotta G; Frezzato F; Visentin A; Ciofini S; Gozzetti A; Bocchia M; Calzada-Fraile D; Martin Cofreces NB; Trentin L; Patrussi L; Baldari CT
Cell Death Dis; 2024 Feb; 15(2):144. PubMed ID: 38360867
[TBL] [Abstract][Full Text] [Related]
4. P66Shc: A Pleiotropic Regulator of B Cell Trafficking and a Gatekeeper in Chronic Lymphocytic Leukemia.
Patrussi L; Capitani N; Baldari CT
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32325830
[TBL] [Abstract][Full Text] [Related]
5. Enhanced IL-9 secretion by p66Shc-deficient CLL cells modulates the chemokine landscape of the stromal microenvironment.
Patrussi L; Manganaro N; Capitani N; Ulivieri C; Tatangelo V; Libonati F; Finetti F; Frezzato F; Visentin A; D'Elios MM; Trentin L; Semenzato G; Baldari CT
Blood; 2021 Apr; 137(16):2182-2195. PubMed ID: 33181836
[TBL] [Abstract][Full Text] [Related]
6. Control of PD-L1 expression in CLL-cells by stromal triggering of the Notch-c-Myc-EZH2 oncogenic signaling axis.
Böttcher M; Bruns H; Völkl S; Lu J; Chartomatsidou E; Papakonstantinou N; Mentz K; Büttner-Herold M; Zenz T; Herling M; Huber W; Ghia P; Stamatopoulos K; Mackensen A; Mougiakakos D
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931470
[TBL] [Abstract][Full Text] [Related]
7. A novel class of oxazepine-based anti-cancer agents induces cell death in primary human CLL cells and efficiently reduces tumor growth in Eμ-TCL1 mice through the JNK/STAT4/p66Shc axis.
Vanni F; Lopresti L; Zurli V; Kabanova A; Cattaneo F; Sicuranza A; Gozzetti A; Gemma S; Zisterer DM; Bocchia M; Campiani G; Baldari CT; Butini S; Ulivieri C
Pharmacol Res; 2021 Dec; 174():105965. PubMed ID: 34732370
[TBL] [Abstract][Full Text] [Related]
8. HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 Model.
Maharaj K; Powers JJ; Mediavilla-Varela M; Achille A; Gamal W; Quayle S; Jones SS; Sahakian E; Pinilla-Ibarz J
Front Immunol; 2020; 11():590072. PubMed ID: 33329575
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model.
McClanahan F; Riches JC; Miller S; Day WP; Kotsiou E; Neuberg D; Croce CM; Capasso M; Gribben JG
Blood; 2015 Jul; 126(2):212-21. PubMed ID: 25979947
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia.
McClanahan F; Hanna B; Miller S; Clear AJ; Lichter P; Gribben JG; Seiffert M
Blood; 2015 Jul; 126(2):203-11. PubMed ID: 25800048
[TBL] [Abstract][Full Text] [Related]
11. CD73 Promotes Chronic Lymphocytic Leukemia.
Allard D; Chrobak P; Bareche Y; Allard B; Tessier P; Bergeron MA; Johnson NA; Stagg J
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804900
[TBL] [Abstract][Full Text] [Related]
12. Expression of the p66Shc protein adaptor is regulated by the activator of transcription STAT4 in normal and chronic lymphocytic leukemia B cells.
Cattaneo F; Patrussi L; Capitani N; Frezzato F; D'Elios MM; Trentin L; Semenzato G; Baldari CT
Oncotarget; 2016 Aug; 7(35):57086-57098. PubMed ID: 27494881
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia.
Rivas JR; Liu Y; Alhakeem SS; Eckenrode JM; Marti F; Collard JP; Zhang Y; Shaaban KA; Muthusamy N; Hildebrandt GC; Fleischman RA; Chen L; Thorson JS; Leggas M; Bondada S
Leukemia; 2021 Nov; 35(11):3188-3200. PubMed ID: 33731852
[TBL] [Abstract][Full Text] [Related]
14. p66Shc deficiency in the Eμ-TCL1 mouse model of chronic lymphocytic leukemia enhances leukemogenesis by altering the chemokine receptor landscape.
Patrussi L; Capitani N; Ulivieri C; Manganaro N; Granai M; Cattaneo F; Kabanova A; Mundo L; Gobessi S; Frezzato F; Visentin A; Finetti F; Pelicci PG; D'Elios MM; Trentin L; Semenzato G; Leoncini L; Efremov DG; Baldari CT
Haematologica; 2019 Oct; 104(10):2040-2052. PubMed ID: 30819907
[TBL] [Abstract][Full Text] [Related]
15. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
16. [Research on the effect of PD-L1 overexpression on CLL-1 CAR-T anti-acute myeloid leukemia].
Lin GQ; Zhang YM; Kang LQ; Yu L; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2020 Oct; 41(10):829-835. PubMed ID: 33190440
[No Abstract] [Full Text] [Related]
17. p66Shc deficiency enhances CXCR4 and CCR7 recycling in CLL B cells by facilitating their dephosphorylation-dependent release from β-arrestin at early endosomes.
Patrussi L; Capitani N; Cattaneo F; Manganaro N; Gamberucci A; Frezzato F; Martini V; Visentin A; Pelicci PG; D'Elios MM; Trentin L; Semenzato G; Baldari CT
Oncogene; 2018 Mar; 37(11):1534-1550. PubMed ID: 29326436
[TBL] [Abstract][Full Text] [Related]
18. S1P1 expression is controlled by the pro-oxidant activity of p66Shc and is impaired in B-CLL patients with unfavorable prognosis.
Capitani N; Patrussi L; Trentin L; Lucherini OM; Cannizzaro E; Migliaccio E; Frezzato F; Gattazzo C; Forconi F; Pelicci P; Semenzato G; Baldari CT
Blood; 2012 Nov; 120(22):4391-9. PubMed ID: 23033271
[TBL] [Abstract][Full Text] [Related]
19. CD84 regulates PD-1/PD-L1 expression and function in chronic lymphocytic leukemia.
Lewinsky H; Barak AF; Huber V; Kramer MP; Radomir L; Sever L; Orr I; Mirkin V; Dezorella N; Shapiro M; Cohen Y; Shvidel L; Seiffert M; Herishanu Y; Becker-Herman S; Shachar I
J Clin Invest; 2018 Dec; 128(12):5465-5478. PubMed ID: 30277471
[TBL] [Abstract][Full Text] [Related]
20. Modified Biejia Jianwan decoction restrains PD-L1-mediated immune evasion through the HIF-1α/STAT3/NF-κB signaling pathway.
Tian X; Liu F; Wang Z; Zhang J; Liu Q; Zhang Y; Zhang D; Huang C; Zhao J; Jiang S
J Ethnopharmacol; 2024 Mar; 322():117577. PubMed ID: 38104877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
